These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28472989)

  • 1. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
    Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
    J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
    Morelli MP; Overman MJ; Dasari A; Kazmi SMA; Mazard T; Vilar E; Morris VK; Lee MS; Herron D; Eng C; Morris J; Kee BK; Janku F; Deaton FL; Garrett C; Maru D; Diehl F; Angenendt P; Kopetz S
    Ann Oncol; 2015 Apr; 26(4):731-736. PubMed ID: 25628445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Uchida J; Imamura F; Kukita Y; Oba S; Kumagai T; Nishino K; Inoue T; Kimura M; Kato K
    Cancer Sci; 2016 Mar; 107(3):353-8. PubMed ID: 26678713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 6. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
    J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal Architecture of
    Ai X; Cui J; Zhang J; Chen R; Lin W; Xie C; Liu A; Zhang J; Yang W; Hu X; Hu X; Zhao Q; Rao C; Zang YS; Ning R; Li P; Chang L; Yi X; Lu S
    Clin Cancer Res; 2021 Feb; 27(3):704-712. PubMed ID: 33188140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
    Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
    Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A
    Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.
    Thierry AR; El Messaoudi S; Mollevi C; Raoul JL; Guimbaud R; Pezet D; Artru P; Assenat E; Borg C; Mathonnet M; De La Fouchardière C; Bouché O; Gavoille C; Fiess C; Auzemery B; Meddeb R; Lopez-Crapez E; Sanchez C; Pastor B; Ychou M
    Ann Oncol; 2017 Sep; 28(9):2149-2159. PubMed ID: 28911069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
    Imamura F; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Kato K
    Lung Cancer; 2016 Apr; 94():68-73. PubMed ID: 26973209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
    O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
    Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
    Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
    Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.
    Lee Y; Park S; Kim WS; Lee JC; Jang SJ; Choi J; Choi CM
    Thorac Cancer; 2018 Sep; 9(9):1104-1110. PubMed ID: 29989342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
    Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
    Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.
    Chen H; Wang A; Wang J; He Z; Mao Y; Liu L
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1867-1876. PubMed ID: 32221744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.